Form 4: Guardant Health CLO Vests Shares, Sells for Tax

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• John G. Saia, Chief Legal Officer of Guardant Health, Inc., reported transactions on March 15, 2026, involving the acquisition and disposition of common stock.
• He acquired 7,792 shares of Common Stock through the vesting of performance-based restricted stock units (RSUs) granted on June 7, 2023, as the second tranche performance metric was achieved.
• An additional 1,019 shares of Common Stock were acquired from the vesting of a restricted stock unit award granted on June 9, 2023.
• A total of 4,622 shares were disposed of at a price of $85.49 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these reported transactions, John G. Saia beneficially owns 56,903 shares of Guardant Health, Inc. Common Stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine vesting of executive compensation, including performance-based awards, which indicates the achievement of internal metrics.

Positives

• The vesting of 7,792 performance-based restricted stock units indicates that the company achieved a specific performance metric for the second tranche of an award granted on June 7, 2023.

Future Outlook

The remaining 67% of the restricted stock unit award granted on June 9, 2023, will vest in equal quarterly installments over the two-year period following June 15, 2024.

Industry Context

StockSavvy.ai notes that insider transactions, such as the vesting of restricted stock units and subsequent sales for tax purposes, are routine events in executive compensation. For Guardant Health, a company operating in the precision oncology sector, these filings provide transparency into executive share ownership and compensation structures, which is standard practice across the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and changes in insider ownership, which is a standard disclosure for publicly traded companies.

Next Steps

• The remaining 67% of the restricted stock unit award granted on June 9, 2023, is scheduled to vest in equal quarterly installments over the two-year period following June 15, 2024.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of restricted stock units and a tax-related sale. It does not contain new material information that would alter the fundamental investment thesis for Guardant Health, thus a 'hold' recommendation is appropriate.

Keywords

Guardant Health, GH, John G. Saia, Form 4, insider transaction, RSU vesting, stock award, Chief Legal Officer, executive compensation